IBDEI0WN ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,42858,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,42858,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,42859,0)
 ;;=C82.60^^127^1855^53
 ;;^UTILITY(U,$J,358.3,42859,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42859,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,42859,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,42859,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,42860,0)
 ;;=D56.2^^127^1855^54
 ;;^UTILITY(U,$J,358.3,42860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42860,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,42860,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,42860,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,42861,0)
 ;;=D75.9^^127^1855^55
 ;;^UTILITY(U,$J,358.3,42861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42861,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,42861,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,42861,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,42862,0)
 ;;=D59.0^^127^1855^58
 ;;^UTILITY(U,$J,358.3,42862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42862,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,42862,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,42862,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,42863,0)
 ;;=D59.2^^127^1855^59
 ;;^UTILITY(U,$J,358.3,42863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42863,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,42863,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,42863,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,42864,0)
 ;;=R59.9^^127^1855^62
 ;;^UTILITY(U,$J,358.3,42864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42864,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,42864,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,42864,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,42865,0)
 ;;=D47.3^^127^1855^63
 ;;^UTILITY(U,$J,358.3,42865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42865,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,42865,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,42865,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,42866,0)
 ;;=C82.09^^127^1855^64
 ;;^UTILITY(U,$J,358.3,42866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42866,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,42866,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,42866,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,42867,0)
 ;;=C82.00^^127^1855^65
 ;;^UTILITY(U,$J,358.3,42867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42867,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,42867,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,42867,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,42868,0)
 ;;=C82.19^^127^1855^66
 ;;^UTILITY(U,$J,358.3,42868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42868,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,42868,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,42868,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,42869,0)
 ;;=C82.10^^127^1855^67
 ;;^UTILITY(U,$J,358.3,42869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42869,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,42869,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,42869,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,42870,0)
 ;;=C82.29^^127^1855^68
 ;;^UTILITY(U,$J,358.3,42870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42870,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,42870,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,42870,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,42871,0)
 ;;=C82.20^^127^1855^69
 ;;^UTILITY(U,$J,358.3,42871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42871,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,42871,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,42871,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,42872,0)
 ;;=C82.39^^127^1855^70
 ;;^UTILITY(U,$J,358.3,42872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42872,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,42872,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,42872,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,42873,0)
 ;;=C82.30^^127^1855^71
 ;;^UTILITY(U,$J,358.3,42873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42873,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,42873,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,42873,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,42874,0)
 ;;=C82.49^^127^1855^72
 ;;^UTILITY(U,$J,358.3,42874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42874,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,42874,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,42874,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,42875,0)
 ;;=C82.40^^127^1855^73
 ;;^UTILITY(U,$J,358.3,42875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42875,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,42875,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,42875,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,42876,0)
 ;;=C82.99^^127^1855^74
 ;;^UTILITY(U,$J,358.3,42876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42876,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,42876,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,42876,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,42877,0)
 ;;=C82.90^^127^1855^75
 ;;^UTILITY(U,$J,358.3,42877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42877,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,42877,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,42877,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,42878,0)
 ;;=R59.1^^127^1855^60
 ;;^UTILITY(U,$J,358.3,42878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42878,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,42878,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,42878,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,42879,0)
 ;;=C91.40^^127^1855^79
 ;;^UTILITY(U,$J,358.3,42879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42879,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,42879,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,42879,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,42880,0)
 ;;=C91.42^^127^1855^77
 ;;^UTILITY(U,$J,358.3,42880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42880,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,42880,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,42880,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,42881,0)
 ;;=C91.41^^127^1855^78
 ;;^UTILITY(U,$J,358.3,42881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42881,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,42881,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,42881,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,42882,0)
 ;;=D57.01^^127^1855^80
 ;;^UTILITY(U,$J,358.3,42882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42882,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,42882,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,42882,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,42883,0)
 ;;=D57.00^^127^1855^81
 ;;^UTILITY(U,$J,358.3,42883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42883,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,42883,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,42883,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,42884,0)
 ;;=D57.02^^127^1855^82
 ;;^UTILITY(U,$J,358.3,42884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42884,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,42884,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,42884,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,42885,0)
 ;;=D68.32^^127^1855^84
 ;;^UTILITY(U,$J,358.3,42885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42885,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,42885,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,42885,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,42886,0)
 ;;=C22.2^^127^1855^85
 ;;^UTILITY(U,$J,358.3,42886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42886,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,42886,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,42886,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,42887,0)
 ;;=D58.9^^127^1855^87
 ;;^UTILITY(U,$J,358.3,42887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42887,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,42887,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,42887,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,42888,0)
 ;;=C81.99^^127^1855^88
 ;;^UTILITY(U,$J,358.3,42888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42888,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,42888,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,42888,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,42889,0)
 ;;=C81.90^^127^1855^89
 ;;^UTILITY(U,$J,358.3,42889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42889,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,42889,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,42889,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,42890,0)
 ;;=D89.2^^127^1855^90
 ;;^UTILITY(U,$J,358.3,42890,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42890,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,42890,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,42890,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,42891,0)
 ;;=D05.12^^127^1855^91
 ;;^UTILITY(U,$J,358.3,42891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42891,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,42891,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,42891,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,42892,0)
 ;;=D05.11^^127^1855^92
 ;;^UTILITY(U,$J,358.3,42892,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42892,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,42892,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,42892,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,42893,0)
 ;;=D05.10^^127^1855^93
